Skip to main content
SpringerLink
Log in

Current Strategies for the Identification of Immunogenic Epitopes of Tumor Antigens

  • Chapter
Immunotherapy of Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Peptide-based cancer immunotherapy relies on the identification of epitopes recognized by T-lymphocytes. Because of the high degree of polymorphism of human leukocyte antigens and issues of tumor escape from the immune response, the availability of a wide choice of diverse epitopes is essential for the therapist. There are a number of different approaches for identifying new class I- and class II-restricted target antigens appropriate for immunotherapy and as discussed in this volume, several of these are complimentary. The strategy of “reverse immunology,” which is presented in this chapter, is applied for prediction of tumor-associated antigens by in silico screening sequences of selected proteins for peptides with high binding affinity to different human leukocyte antigen molecules. Subsequently, these peptides are synthesized and tested experimentally. Here, we outline some of the most prominent current algorithms and methods for assessing the immunogenicity of the predicted peptides in vitro and in vivo. We also describe the complimentary approach of isolating major histocompatibility complexassociated peptides from target cells followed by sequencing using reverse phase highpressure liquid chromatography fractionation and mass spectrometric analysis. We conclude by discussing some of the potential advantages and disadvantages of these methods and problems associated with their application.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13:1–27.

    PubMed  CAS  Google Scholar 

  2. Rygaard J, Povlsen CO. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. Acta Pathol Microbiol Scand (B) Microbiol Immunol 1974; 82:99–106.

    CAS  Google Scholar 

  3. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971; 28:89–98.

    Article  PubMed  CAS  Google Scholar 

  4. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976; 33:241–259.

    PubMed  CAS  Google Scholar 

  5. Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 1982; 79:4718–4722.

    Article  PubMed  Google Scholar 

  6. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002; 14:178–182.

    Article  PubMed  CAS  Google Scholar 

  7. Parmiani G. Vaccine therapy of cancer. Suppl Tumori 2002; 1(Suppl):S28.

    PubMed  Google Scholar 

  8. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643–1647.

    Article  PubMed  Google Scholar 

  9. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176:1453–1457.

    Article  PubMed  CAS  Google Scholar 

  10. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994; 91:9461–9465.

    Article  PubMed  CAS  Google Scholar 

  11. Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res 1999; 59:5785–5792.

    PubMed  CAS  Google Scholar 

  12. Brandle D, Brasseur F, Weynants P, Boon T, Van den EB. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 1996; 183:2501–2508.

    Article  PubMed  CAS  Google Scholar 

  13. Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 1999; 162:1730–1738.

    PubMed  CAS  Google Scholar 

  14. Echchakir H, Mami-Chouaib F, Vergnon I, et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001; 61:4078–4083.

    PubMed  CAS  Google Scholar 

  15. Maccalli C, Li YF, El Gamil M, Rosenberg SA, Robbins PF. Identification of a colorectal tumorassociated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res 2003; 63:6735–6743.

    PubMed  CAS  Google Scholar 

  16. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997; 186:785–793.

    Article  PubMed  CAS  Google Scholar 

  17. Gueguen M, Patard JJ, Gaugler B, et al. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol 1998; 160:6188–6194.

    PubMed  CAS  Google Scholar 

  18. Klein G. Dysregulation of lymphocyte proliferation by chromosomal translocations and sequential genetic changes. Bioessays 2000; 22:414–422.

    Article  PubMed  CAS  Google Scholar 

  19. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2004; 54:187–207.

    Article  PubMed  CAS  Google Scholar 

  20. Baurain JF, Colau D, van Baren N, et al. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J Immunol 2000; 164:6057–6066.

    PubMed  CAS  Google Scholar 

  21. Karanikas V, Colau D, Baurain JF, et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001; 61:3718–3724.

    PubMed  CAS  Google Scholar 

  22. Novellino L, Renkvist N, Rini F, et al. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J Immunol 2003; 170:6363–6370.

    PubMed  CAS  Google Scholar 

  23. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line-and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999; 19:7327–7335.

    PubMed  Google Scholar 

  24. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004; 4:1.

    PubMed  Google Scholar 

  25. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993; 177:989–998

    Article  PubMed  CAS  Google Scholar 

  26. Nelson PS, Gan L, Ferguson C, et al. Molecular cloning and characterization of prostase, an androgenregulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 1999; 96:3114–3119

    Article  PubMed  CAS  Google Scholar 

  27. Stephenson SA, Verity K, Ashworth LK, Clements JA. Localization of a new prostate-specific antigenrelated serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem 1999; 274:23,210–23,214.

    Article  PubMed  CAS  Google Scholar 

  28. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982–990.

    Article  PubMed  CAS  Google Scholar 

  29. Gromme M, Neefjes J. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 2002; 39:181–202.

    Article  PubMed  CAS  Google Scholar 

  30. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351:290–296.

    Article  PubMed  CAS  Google Scholar 

  31. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213–219.

    Article  PubMed  CAS  Google Scholar 

  32. Sturniolo T, Bono E, Ding J, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17:555–561.

    Article  PubMed  CAS  Google Scholar 

  33. Toes RE, Nussbaum AK, Degermann S, et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001; 194:1–12.

    Article  PubMed  CAS  Google Scholar 

  34. Nussbaum AK, Kuttler C, Tenzer S, Schild H. Using the World Wide Web for predicting CTL epitopes. Curr Opin Immunol 2003; 15:69–74.

    Article  PubMed  CAS  Google Scholar 

  35. Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, Schild H. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 2001; 53:87–94.

    Article  PubMed  CAS  Google Scholar 

  36. Kesmir C, Nussbaum AK, Schild H, Detours V, Brunak S. Prediction of proteasome cleavage motifs by neural networks. Protein Eng 2002; 15:287–296.

    Article  PubMed  CAS  Google Scholar 

  37. Holzhutter HG, Frommel C, Kloetzel PM. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. J Mol Biol 1999; 286:1251–1265.

    Article  PubMed  CAS  Google Scholar 

  38. Schultz ES, Chapiro J, Lurquin C, et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med 2002; 195:391–399.

    Article  PubMed  CAS  Google Scholar 

  39. Dissemond J, Goette P, Moers J, et al. Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression. Melanoma Res 2003; 13:371–377.

    Article  PubMed  CAS  Google Scholar 

  40. Meidenbauer N, Zippelius A, Pittet MJ, et al. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 2004; 64:6319–6326.

    Article  PubMed  CAS  Google Scholar 

  41. Hakenberg J, Nussbaum AK, Schild H, et al. MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics 2003; 2:155–158.

    PubMed  CAS  Google Scholar 

  42. Reche PA, Glutting JP, Reinherz EL. Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 2002; 63:701–709.

    Article  PubMed  CAS  Google Scholar 

  43. Reche PA, Glutting JP, Zhang H, Reinherz EL. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 2004; 56:405–419.

    Article  PubMed  CAS  Google Scholar 

  44. Saxova P, Buus S, Brunak S, Kesmir C. Predicting proteasomal cleavage sites: a comparison of available methods. Int Immunol 2003; 15:781–787.

    Article  PubMed  CAS  Google Scholar 

  45. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through posttranslational protein splicing. Nature 2004; 427:252–256.

    Article  PubMed  CAS  Google Scholar 

  46. Vigneron N, Stroobant V, Chapiro J, et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 2004; 304:587–590.

    Article  PubMed  CAS  Google Scholar 

  47. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004; 4:401–411.

    Article  PubMed  CAS  Google Scholar 

  48. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113:1515–1525.

    Article  PubMed  CAS  Google Scholar 

  49. Akiyama Y, Maruyama K, Nara N, et al. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. Anticancer Res 2004; 24:571–577.

    PubMed  CAS  Google Scholar 

  50. Müller L, Knights A, Pawelec G. Synthetic peptides derived from the Wilms’ tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells. Hematol J 2003; 4:57–66

    Article  PubMed  CAS  Google Scholar 

  51. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103:1037–1042.

    Article  PubMed  CAS  Google Scholar 

  52. Zeng G, Li Y, El Gamil M, et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002; 62:3630–3635.

    PubMed  CAS  Google Scholar 

  53. Pawelec G, Rees RC, Kiessling R, et al. Cells and cytokines in immunotherapy and gene therapy of cancer. Crit Rev Oncog 1999; 10:83–127.

    PubMed  CAS  Google Scholar 

  54. Fukao T, Matsuda S, Koyasu S. Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J Immunol 2000; 164:64–71.

    PubMed  CAS  Google Scholar 

  55. Müller L, Pawelec G. Chronic phase CML patients possess T cells capable of recognising autologous tumour cells. Leuk Lymphoma 2 2002; 43:943–951.

    Google Scholar 

  56. Kang WK, Park C, Yoon HL, et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001; 12:671–684.

    Article  PubMed  CAS  Google Scholar 

  57. Melero I, Mazzolini G, Narvaiza I, Qian C, Chen L, Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol 2001; 22:113–115.

    Article  PubMed  CAS  Google Scholar 

  58. Paul S, Regulier E, Poitevin Y, Hormann H, Acres RB. The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer. Cancer Immunol Immunother 2002; 51:645–654.

    Article  PubMed  CAS  Google Scholar 

  59. Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999; 162:3231–3236.

    PubMed  CAS  Google Scholar 

  60. Müller L, Provenzani C, Pawelec G. Generation of chronic myelogenous leukemia-specific T cells in cytokine-modified autologous mixed lymphocyte/tumor cell cultures. J Immunother 2 2001; 24:482–492.

    Article  Google Scholar 

  61. Wagner WM, Ouyang Q, Pawelec G. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia. Leukemia 2002; 16:2341–2343.

    Article  PubMed  CAS  Google Scholar 

  62. Wagner WM, Ouyang Q, Pawelec G. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes. Cancer Immunol Immunother 2003; 52:89–96.

    PubMed  CAS  Google Scholar 

  63. Knights AJ, Zaniou A, Rees RC, Pawelec G, Müller L. Prediction of an HLA-DR-binding peptide derived from Wilms’ tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124–138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol Immunother 20 2002; 51:271–281

    Article  CAS  Google Scholar 

  64. Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic polyribocytidylic acid (poly[I:C]) induces stable maturation of functionally active human dendritic cells. J Immunol 1999; 163:57–61.

    PubMed  CAS  Google Scholar 

  65. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003; 9:619–624.

    Article  PubMed  CAS  Google Scholar 

  66. Walter S, Herrgen L, Schoor O, et al. Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. J Immunol 2003; 171:4974–4978.

    PubMed  CAS  Google Scholar 

  67. Oelke M, Schneck JP. HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement. Clin Immunol 2004; 110:243–251.

    Article  PubMed  CAS  Google Scholar 

  68. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65–78.

    Article  PubMed  CAS  Google Scholar 

  69. Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9:1377–1382.

    Article  PubMed  CAS  Google Scholar 

  70. Britten CM, Müller L, Knights A, Pawelec G. Cancer Immunotherapy 2 dy2004: Mainz, Germany, 6–7 May 2004). Cancer Immunol Immunother 2004;53:1153–1158.

    Article  PubMed  CAS  Google Scholar 

  71. Firat H, Cochet M, Rohrlich PS, et al. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int Immunol 2002; 14:925–934.

    Article  PubMed  CAS  Google Scholar 

  72. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185:2043–2051.

    Article  PubMed  CAS  Google Scholar 

  73. Ramage JM, Metheringham R, Moss R, Spendlove I, Rees R, Durrant LG. Comparison of the immune response to a self antigen after DNA immunisation of HLA*A201/H-2Kb and HHD transgenic mice. Vaccine 2004; 22:1728–1731.

    Article  PubMed  CAS  Google Scholar 

  74. Pascolo S, Schirle M, Guckel B, et al. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res 2001; 61:4072–4077.

    PubMed  CAS  Google Scholar 

  75. Corbet S, Nielsen HV, Vinner L, et al. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. J Gen Virol 2003; 84:2409–2421

    Article  PubMed  CAS  Google Scholar 

  76. Gritzapis AD, Sotiriadou NN, Papamichail M, Baxevanis CN. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors. Cancer Immunol Immunother 2004; 53:1027–1040.

    Article  PubMed  Google Scholar 

  77. Shi TD, Wu YZ, Jia ZC, Zhou W, Zou LY. Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice. World J Gastroenterol 2004; 10:1222–1226.

    PubMed  CAS  Google Scholar 

  78. Himoudi N, Abraham JD, Fournillier A, et al. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol 2002; 76:12,735–12,746.

    Article  PubMed  CAS  Google Scholar 

  79. Theobald M, Ruppert T, Kuckelkorn U, et al. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 1998; 188:1017–1028.

    Article  PubMed  CAS  Google Scholar 

  80. Sonderstrup G, Cope AP, Patel S, et al. HLA class II transgenic mice: models of the human CD4+ Tcell immune response. Immunol Rev 1999; 172:335–343.

    Article  PubMed  CAS  Google Scholar 

  81. Rojas JM, McArdle SE, Horton RB, et al. Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*. Cancer Immunol Immunother 2004; 54:243–253.

    Article  PubMed  CAS  Google Scholar 

  82. Pajot A, Pancre V, Fazilleau N, et al. Comparison of HLA-DR1-restricted T cell response induced in HLA-DR1 transgenic mice deficient for murine MHC class II and HLA-DR1 transgenic mice expressing endogenous murine MHC class II molecules. Int Immunol 2004; 16:1275–1282.

    Article  PubMed  CAS  Google Scholar 

  83. Zhou H, Luo Y, Mizutani M, et al. A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J Clin Invest 2004; 113:1792–1798.

    Article  PubMed  CAS  Google Scholar 

  84. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 2000; 192:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  85. Haurum JS, Hoier IB, Arsequell G, et al. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 1999; 190:145–150.

    Article  PubMed  CAS  Google Scholar 

  86. Van den Steen PE, Proost P, Brand DD, Kang AH, Van Damme J, Opdenakker G. Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B. Biochemistry 2004; 43:10,809–10,816.

    Article  PubMed  CAS  Google Scholar 

  87. Skipper JC, Hendrickson RC, Gulden PH, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996; 183:527–534.

    Article  PubMed  CAS  Google Scholar 

  88. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171:538–541.

    PubMed  CAS  Google Scholar 

  89. Parham P. Purification of immunologically active HLA-A and-B antigens by a series of monoclonal antibody columns. J Biol Chem 1979; 254:8709–8712.

    PubMed  CAS  Google Scholar 

  90. Parham P, Barnstable CJ, Bodmer WF. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol 1979; 123:342–349.

    PubMed  CAS  Google Scholar 

  91. Shackelford DA, Lampson LA, Strominger JL. Separation of three class II antigens from a homozygous human B cell line. J Immunol 1983; 130:289–296.

    PubMed  CAS  Google Scholar 

  92. Storkus WJ, Zeh HJ III, Salter RD, Lotze MT. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 1993; 14:94–103.

    Article  CAS  Google Scholar 

  93. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995; 181:363–368.

    Article  PubMed  CAS  Google Scholar 

  94. Clark RE, Dodi IA, Hill SC, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98:2887–2893.

    Article  PubMed  CAS  Google Scholar 

  95. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264:716–719.

    Article  PubMed  CAS  Google Scholar 

  96. McDonald WH, Yates JR III. Shotgun proteomics and biomarker discovery. Dis Markers 2002; 18:99–105.

    PubMed  CAS  Google Scholar 

  97. Stevanovic S, Jung G. Multiple sequence analysis: pool sequencing of synthetic and natural peptide libraries. Anal Biochem 1993; 212:212–220.

    Article  PubMed  CAS  Google Scholar 

  98. Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992; 255:1261–1263.

    Article  PubMed  CAS  Google Scholar 

  99. Chicz RM, Urban RG, Lane WS, et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992; 358:764–768.

    Article  PubMed  CAS  Google Scholar 

  100. Spengler B. De novo sequencing, peptide composition analysis, and composition-based sequencing: a new strategy employing accurate mass determination by Fourier transform ion cyclotron resonance mass spectrometry. J Am Soc Mass Spectrom 2004; 15:703–714.

    Article  PubMed  CAS  Google Scholar 

  101. Flad T, Spengler B, Kalbacher H, et al. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res 1998; 58:5803–5811.

    PubMed  CAS  Google Scholar 

  102. De Groot AS, Sbai H, Aubin CS, McMurry J, Martin W. Immuno-informatics: mining genomes for vaccine components. Immunol Cell Biol 2002; 80:255–269.

    Article  PubMed  Google Scholar 

  103. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270:467–470.

    Article  PubMed  CAS  Google Scholar 

  104. Boer JM, Huber WK, Sultmann H, et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 2001; 11:1861–1870.

    PubMed  CAS  Google Scholar 

  105. Weinschenk T, Gouttefangeas C, Schirle M, Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002; 62:5818–5827.

    PubMed  CAS  Google Scholar 

  106. Lemmel C, Weik S, Eberle U, et al. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol 2004; 22:450–454.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section for Transplantation Immunology, Centre for Medical Research, University of Tübingen Medical School, Tübingen, Germany

    Ludmila Müller PhD, Evelyna Derhovanessian DIPL BIOL, Thomas Flad PhD, Ashley Knights MSC & Graham Pawelec PhD

  2. The School of Biomedical and Natural Sciences, The Nottingham Trent University, Nottingham, UK

    Stephanie McArdle PhD & Robert Rees PhD

Authors
  1. Ludmila Müller PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie McArdle PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evelyna Derhovanessian DIPL BIOL
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Flad PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ashley Knights MSC
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert Rees PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Graham Pawelec PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Washington School of Medicine, Seattle, WA

    Mary L. Disis MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Müller, L. et al. (2006). Current Strategies for the Identification of Immunogenic Epitopes of Tumor Antigens. In: Disis, M.L. (eds) Immunotherapy of Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59745-011-1:021

Download citation

Publish with us

Policies and ethics

Search

Navigation